Exploring tisotumab vedotin in recurrent cervical cancer: A case series including an HPV-independent gastric type adenocarcinoma
Metastatic and recurrent cervical cancer is difficult to treat with limited options following platinum-based chemotherapy. Tisotumab vedotin (TV) is an antibody drug conjugate (ADC) targeted at a tissue factor (TF), which is a cell surface protein that is upregulated in the majority of cervical canc...
Saved in:
Main Authors: | Lisa Marie Babayan (Author), Catherine Bouts (Author), Saketh Guntupalli (Author), Nicole A. Marjon (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2024-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tisotumab vedotin extravasation injury in a patient with recurrent cervical cancer
by: Ji Son, et al.
Published: (2024) -
Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and/or metastatic solid tumors
by: Leonid Gibiansky, et al.
Published: (2022) -
Exposure‐safety and exposure‐efficacy analyses for tisotumab vedotin for patients with locally advanced or metastatic solid tumors
by: Chaitali Passey, et al.
Published: (2023) -
Comments on: Limitations of HPV DNA Testing in Screening of Cervical Adenocarcinomas
by: Laurence M. Vaughan, et al.
Published: (2019) -
Comments on: Limitations of HPV DNA Testing in Screening of Cervical Adenocarcinomas
by: Marcos Emanuel de Alcântara Segura
Published: (2019)